El interés en corto de TFI International da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de TFI International. Los datos de interés en corto se actualizan cada dos semanas.

TFI International (NYSE:TFII) Bolsa, Informe de interés en corto

TFI International

TFI International Inc is a transportation and logistics company domiciled in Canada. The company organizes itself into four segments: package and courier, less-than-truckload, truckload, and logistics. The package and courier segment picks up, transports, and delivers items across North America. The less-than-truckload segment transports smaller loads. The truckload segment transports goods by flatbed trucks, containers, or a more specialized service. The company provides general logistics services through the logistics segment. TFI International derives the majority of its revenue domestically, followed by the United States.

TFI International Inc

-Data demonstrate characteristics essential for treatment of autoimmune diseases, including robust tissue homing and complete CD19+ B cell depletion in secondary lymphoid tissue
-Results highlight the potential benefits unique to gamma delta 1 CAR T cell therapy and ADI-001's potential as a best-in-class off-the-shelf cell therapy for autoimmune diseases
-The company is pursuing ADI-001 in a basket study across six indications including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM), stiff person syndrome (SPS) and anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV)

News

ACET

Reported Saturday, Adicet Bio Shared Clinical Biomarker Data On Off-The-Shelf CAR T Cell Therapy During Oral Session At ACR Convergence 2024

<ul>
<li>In a first-of-its-kind study, tirzepatide also alleviated heart failure symptoms and physical limitations</li>
<li>Patients on tirzepatide experienced improved exercise capacity, greater weight loss and reduced systemic inflammation</li>
<li>Lilly has initiated submissions for tirzepatide for the treatment of HFpEF and obesity to global regulatory agencies</li>
</ul>

Reported Saturday, Eli Lilly's Tirzepatide Cuts Heart Failure Risk By 38% In Adults With Heart Failure With Preserved Ejection Fraction (HFpEF) And Obesity

On Sunday, President-elect Donald Trump picked pro-Starlink Republican Brendan Carr as chairman of the Federal Communications Commission, or FCC.
What Happened: &#8220;Commissioner Carr is a warrior for Free Speech, and has fought against the regulatory Lawfare that has stifled Americans&#8217; Freedoms, and held back our Economy. He will end the regulatory onslaught that has been crippling America&#8217;s Job Creators and Innovators, and ensure that the FCC delivers for rural America,&#8221; Trump wrote in his statement. 
Carr, a vocal critic of big tech companies, wrote on X that he is &#8220;humbled and noted&#8221; to take on the role. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Thank you, President Trump! I am humbled and honored to serve as Chairman of the FCC. Now we get to work. &#x1f1fa;&#x1f1f8; <a href="https://t.co/MPyL2d38kT">pic.twitter.com/MPyL2d38kT</a>
&mdash; Brendan Carr (@BrendanCarrFCC) <a href="https://twitter.com/BrendanCarrFCC/status/1858311955024400868?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Carr wrote last week that &#8220;Facebook, Google, Apple, Microsoft, and others have played central roles in the censorship cartel,&#8221; adding that they must be &#8220;dismantled.&#8221;
Carr currently serves as the senior Republican on the FCC. The FCC is an independent U.S. government agency overseen by Congress and regulates interstate and international communications by radio, television, wire, satellite, and cable in all 50 states, the District of Columbia, and U.S. territories. 
Jessica Rosenworcel currently serves as the Chairperson of the Commission. 
Why It Matters: Carr is a strong supporter of Musk&#8217;s Starlink. He staunchly <a href="https://www.benzinga.com/news/24/09/40672229/starlink-ineligible-for-nearly-900m-in-subsidies-says-fcc-spacex-ceo-elon-musk-says-it-is-flat-out-l">opposed the FCC&#8217;s decision not to offer nearly $900 million in subsidies to Starlink</a> alleging that the FCC had added itself to the growing list of administrative agencies taking action against Musk's businesses following the billionaire's acquisition of Twitter (now X) on the instructions of President Joe Biden. 
Carr also said on Monday that the FCC will stop promoting Diversity, Equity, Inclusion, and Accessibility (DEI) initiatives.
&#8220;The FCC's most recent budget request said that promoting DEI was the agency's second-highest strategic goal. Starting next year, the FCC will end its promotion of DEI,&#8221; he wrote on X. 
Musk is also staunchly <a href="https://www.benzinga.com/news/24/04/38064076/mark-cuban-vows-to-defend-deis-positive-impact-on-business-because-they-are-opposite-of-elon-musk-an">opposed to DEI programs</a>, terming them &#8220;racist.&#8221; Musk regards preference for certain sections of the population in DEI programs as &#8220;racism&#8221; towards the majority white population. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42025362/former-uber-executive-and-3-congressmen-contenders-for-trumps-transportation-chief-role-report">Former Uber Executive And 3 Congressmen Contenders For Trump&#8217;s Transportation Chief Role: Report</a></li>
</ul>
Photo courtesy: Gage Skidmore via Flickr

SPACE

Tech

Trump Names Pro-Starlink FCC Commissioner Brendan Carr As Chairperson, Says He Will 'End The Regulatory Onslaught'

<ul>
<li>Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time treatment of nex-z, supporting the hypothesis that greater TTR reduction may lead to a greater clinical benefit in ATTR amyloidosis</li>
<li>Favorable trends consistently observed across multiple markers of cardiac disease progression at month 12 compared to baseline in an ATTR-CM population with a high proportion of advanced heart failure patients</li>
<li>Consistent trend observed to date in ATTRv-PN arm, with stability or improvement of neuropathy as measured by multiple clinical measures of disease progression compared to baseline</li>
<li>Persistently deep levels of serum TTR reductions following a single infusion remain virtually unchanged after two or more years of follow-up in over 25 patients</li>
<li>Favorable safety and tolerability profile observed</li>
<li>ATTR-CM data presented at the 2024 AHA Scientific Sessions and published in the New England Journal of Medicine</li>
</ul>

NTLA

Reported Saturday, Intellia Announced Initial Phase 1 Data Suggesting Nexiguran Ziclumeran, An In Vivo CRISPR/Cas9 Gene Editing Therapy, May Benefit ATTR Amyloidosis Progression

BMRN

Reported Saturday, BioMarin Presents Real-World Data On VOXZOGO Efficacy And Safety In Children With Achondroplasia At ESPE 2024

BioCryst Pharmaceuticals, Inc.&nbsp;(Nasdaq:&nbsp;BCRX) today announced that the Health Services Executive (HSE) in Ireland has recommended ORLADEYO&#xAE;&nbsp;(berotralstat) for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients 12 years and older. With this recommendation, HAE patients in Ireland will have access to the first oral, once-daily therapy for the reduction of recurrent HAE attacks.
"The positive HSE recommendation of ORLADEYO&nbsp;broadens access to modern prophylaxis, providing greater choice for prescribing physicians and potentially a better quality of life for HAE patients in Ireland," said Charlie Gayer, chief commercial officer of BioCryst.
The HSE decision in Ireland follows the European Commission marketing authorization of ORLADEYO in April 2021. To date, ORLADEYO is licensed in 44 countries.

Government

Regulations

BCRX

BioCryst's ORLADEYO Gets Ireland's Approval: Expanding Access to Once-Daily HAE Therapy

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation

Reported Saturday, Boston Scientific's WATCHMAN FLX Device Shows Superior Bleeding Risk Reduction Compared To Oral Anticoagulants After Cardiac Ablation In OPTION Clinical Trial

<ul>
<li>New preclinical results support the anti-fibrotic potential of engineered macrophages in multiple fibrosis models</li>
<li>Engineered TIM4-expressing macrophages correct defective&nbsp;efferocytosis in MASH, demonstrating potent anti-fibrotic activity&nbsp;</li>
</ul>

CARM

Reported Sunday, Carisma Therapeutics Unveils Preclinical Data On Engineered Macrophages For Liver Fibrosis Treatment At AASLD The Liver Meeting 2024

<ul>
<li>Single Dose of Nucresiran 300mg or Higher Led to Rapid Knockdown of Mean TTR Levels of Greater than 90% by Day 15 that was Sustained at Six Months&nbsp;</li>
<li>At These Doses, Peak Reduction of Mean TTR Levels of Greater than 96% were Achieved by Day 29 −</li>
<li>Data Support Potential for Biannual or Annual Subcutaneous Dosing, Representing a New Paradigm in the Treatment of ATTR Amyloidosis −</li>
<li>Encouraging Safety and Tolerability Observed −</li>
<li>Alnylam Continues to Expect to Share Phase 3 Development Plans in Q1 2025 –</li>
</ul>

ALNY

Reported Sunday, Alnylam Reported Interim Phase 1 Results For Nucresiran (ALN-TTRsc04), Demonstrating Rapid And Sustained TTR Reduction Lasting Six Months After A Single Dose

"The preclinical data presented at ACR Convergence underscore the exceptional potential of our targeted protein degradation strategy compared to kinase inhibition for both BTK and IRAK4, which are critical targets in inflammatory and autoimmune diseases, and support continued advancement of these drug candidates into clinical studies," said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix. "These programs showcase the capability of Nurix's DELigase platform to generate potent best-in-class degrader drug candidates with the potential to deliver superior efficacy in several inflammatory diseases."

NRIX

Reported Sunday, Nurix Therapeutics Showcased Preclinical Data On NX-5948 And GS-6791 From Autoimmune And Inflammatory Disease Programs At ACR Convergence 2024

<ul>
<li>ELAHERE is the first and only novel therapy approved in the European Union specifically for patients with folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer</li>
<li>ELAHERE represents the first treatment to demonstrate an overall survival benefit in a Phase 3 trial in platinum-resistant ovarian cancer compared with chemotherapy</li>
<li>VENTANA FOLR1 (FOLR1-2.1)&nbsp;RxDx Assay, the companion diagnostic to identify ovarian cancer patients eligible for ELAHERE, also receives CE Mark</li>
</ul>

ABBV

AbbVie Secures European Commission Approval For ELAHERE, First Novel Therapy For Platinum-Resistant Ovarian Cancer

<ul>
<li>The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay detects the folate receptor 1 protein (FOLR1 or FRɑ), which is over-expressed in most ovarian cancers.</li>
<li>The test identifies ovarian cancer patients eligible for targeted treatment with ELAHERE. &nbsp;</li>
<li>This certification follows the unprecedented decision by regulators to grant an early exemption approval for the test in Germany and Austria earlier this year.</li>
</ul>

RHHBF

RHHBY

Roche Secures CE Mark For VENTANA FOLR1 RxDx Assay, The First IHC Diagnostic For Identifying Epithelial Ovarian Cancer Patients Eligible For ELAHERE

<ul>
<li>Revere Medical Enters into Agreement to Acquire CareMax's Management Services Organization</li>
<li>Agreement in Principle Reached with "Stalking Horse" for Core Centers' Assets</li>
<li>Sale Transactions to be Implemented Through an Expedited Prearranged Chapter 11 Plan Supported by 100% of CareMax's Secured Lenders</li>
<li>CareMax Secures $30.5 Million in Debtor in Possession Financing to Support Operations and Continuing Provision of Healthcare Services Throughout Restructuring Process</li>
</ul>

CMAX

Reported Sunday, CareMax Enters Prearranged Chapter 11, Reaches Deal To Sell MSO And Core Centers' Assets, Secures $30.5M DIP Financing

Reported Sunday, Apollo Opens Seoul Office Amid APAC Expansion, Taps Samsung Securities Veteran Jay Hyun Lee As Head Of Korea

Alibaba intends to use the net proceeds from the offering of the Notes for general corporate purposes, including repayment of offshore debt and share repurchases.

BABA

Reported Sunday, Alibaba Announces Dual Currency Senior Unsecured Notes Offering, Targeting Capital Raise For Debt Repayment And Strategic Share Buybacks

In collaboration with Toronto Metropolitan University, the Government of Canada will invest $3.9M CAD in the Malaysia Cybersecurity Center of Excellence to strengthen cybersecurity partnerships and expertise in the region through skills training opportunities, including for women

Reported Sunday, Blackberry Partners With Canadian Government And TMU To Launch Cybersecurity Training Initiative In Southeast Asia With C$3.9M Investment

This milestone is further celebrated by the anticipated opening of twelve additional Four Points Flex by Sheraton properties across Japan this year, which will also mark the company's entry to key cities such as Morioka and Kanazawa. In collaboration with global investment firm KKR, this conversion-friendly expansion is expected to see a total of 14 properties join the brand in Japan through early 2025, adding over 3,600 rooms to Marriott's growing portfolio across prominent destinations including Hakodate, Utsunomiya, Yokohama, Nagoya, Osaka, Kyoto, Kobe, and Hakata.

Marriott International Marks Milestone With 100th Property In Japan, Launching Four Points Flex By Sheraton In Asia Pacific

Accenture Partners With ETS To Launch Global Skills-Based Talent Management Platform

Renowned tech investor and Palantir Technologies&#8217; co-founder&nbsp;Peter Thiel&nbsp;has made a daring prediction about the potential impact of President-elect Donald Trump&#8217;s <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41902202/trumps-china-hawks-rumored-for-top-roles-yuan-hits-3-month-low">60% tariff on Chinese goods</a>.
What Happened: On Thursday, during an interview with The Free Press, Thiel suggested that such a tariff would be &#8220;very, very bad&#8221; for <a href="https://www.benzinga.com/general/social-media/24/11/41912771/trump-presidency-magnificent-7-stock-impact-benzinga-readers-pick-tech-titan-at-most-risk-following-2024-election">Chinese companies</a> and China as a whole.
However, he believes the impact on American consumers would be &#8220;mildly negative&#8221; as manufacturing would likely shift away from China.
According to Thiel, shifting manufacturing from China to Vietnam would significantly harm China, and have only a minor impact on American consumers. From a geopolitical perspective, he argued, this move would align closely with American strategic interests.
See Also:&nbsp;<a href="https://www.benzinga.com/etfs/24/11/42018463/trumps-post-election-rally-fades-dollar-surges-to-over-1-year-highs-powell-puts-december-interest-rate-cut-into-question-this-week-in-the-market?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Post-Election Rally Fades, Dollar Surges To Over 1-Year Highs, Powell Puts December Interest Rate Cut Into Question: This Week In The Market</a>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Peter Thiel on the Triumph of the Counter-Elites" width="500" height="281" src="https://www.youtube.com/embed/wwJV_NuN43Y?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Why It Matters: Earlier this year, Chinese stocks <a href="https://www.benzinga.com/markets/asia/24/05/38782459/china-focused-etfs-have-become-political-footballs-in-us-as-investor-apprehension-leads-to-large-sca#google_vignette">experienced a notable rally</a>, pushing the SSE Composite Index in Shanghai to its highest point since September 2023.
However, Trump's proposed tariffs, which could reach as high as 60% on Chinese goods, along with additional import hikes on other nations, could disrupt these investments.
A day after Trump won, China-linked ETFs witnessed a sharp fall after rallying for nearly two months.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>China-linked ETFs</td>
<td>Share Price Drop On Nov. 6, 2024</td>
</tr>
<tr>
<td>KraneShares CSI China Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KWEB#NYSE">KWEB</a>)</td>
<td>2.01%</td>
</tr>
<tr>
<td>iShares MSCI China ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHI#NASDAQ">MCHI</a>)</td>
<td>2.70%</td>
</tr>
<tr>
<td>iShares China Large-Cap ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXI#NYSE">FXI</a>)</td>
<td>2.94%</td>
</tr>
</tbody>
</table>
</figure>
U.S.-listed Chinese stocks such as Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>), and XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) also <a href="https://www.benzinga.com/government/24/11/41773691/us-listed-chinese-stocks-like-alibaba-jd-nio-fall-after-trumps-win-whats-going-on">saw a decline in trading</a> following Trump&#8217;s win.
The imposition of such tariffs could strain China's economic growth, negatively impacting the performance of <a href="https://www.benzinga.com/general/social-media/24/11/41912771/trump-presidency-magnificent-7-stock-impact-benzinga-readers-pick-tech-titan-at-most-risk-following-2024-election">China-focused ETFs</a>, particularly those tied to the tech sector and large-cap companies, making them less attractive to investors.
Despite the immediate economic challenges that such a tariff would pose, some experts believe that China may view Trump's return to the White House as <a href="https://www.benzinga.com/news/global/24/11/41870809/china-may-benefit-from-trumps-return-to-white-house-despite-his-tariff-plans-says-expert-short-term-pain-but-potentially-long-term-strategic-gain">an opportunity for strategic advantage</a>.
Earlier this week, Chinese President Xi Jinping also expressed China's willingness to <a href="https://www.benzinga.com/24/11/42025284/xi-jinping-tells-joe-biden-china-is-ready-to-work-with-trump-as-tariff-threat-looms">collaborate with the U.S. government</a>, regardless of the administration in power.
Image via Wikimedia
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41998910/mohamed-el-erian-criticizes-fed-chair-powells-interview-performance-says-responses-left-many-perplexed?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Mohamed El-Erian Criticizes Fed Chair Powell&#8217;s Interview Performance: &#8216;He Struggled With Some Of The Smart Questions&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Politics

Economics

Markets

BIDU

KWEB

MCHI

XPEV

Peter Thiel Says Trump's 60% China Tariff Would Be 'Very, Very Bad' For Beijing, Here's What's At Stake

Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is trading over 5% on Robinhood&#8217;s overnight trading service after a report on Sunday, suggested that the upcoming regulatory framework might ease mandates for self-driving vehicles. 
What Happened: The transition team of President-elect Donald Trump has told advisors that it aims to make a framework for fully self-driving vehicles a priority for the Transportation Department, <a href="https://www.bloomberg.com/news/articles/2024-11-17/trump-team-said-to-want-to-ease-us-rules-for-self-driving-cars">reported</a> Bloomberg, citing people familiar with the matter. 
Tesla CEO Elon Musk recently secured a position to lead the newly created Department of Government Efficiency (DOGE) in the Trump administration, supported federal rules for autonomous vehicles in Tesla&#8217;s third-quarter earnings call, saying he would use any role to push the government to allow autonomous vehicles to be used nationwide. 
National Highway Traffic Safety Administration allows automakers to deploy only 2,500 autonomous vehicles per year, while efforts to increase this number have repeatedly failed. 
See Also: <a href="https://www.benzinga.com/24/11/42028342/blackwell-backfires-nvidias-ai-chips-struggle-with-server-overheating-impacting-meta-microsoft-and-musks-xai-data-centers">Nvidia&#8217;s Blackwell Chips Are Extra Toasty, Server Overheating Issues Impact Meta, Microsoft And Elon Musk&#8217;s xAI</a>
Why It Matters: In October, Musk unveiled Tesla&#8217;s long-awaited robotaxi, which aims to mass produce &#8216;Cybercabs&#8217; by 2026. Investors and market analysts are considering robotaxi&#8217;s success as a major factor for the company&#8217;s valuation, while some investors remain skeptical about <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41444334/tesla-robotaxi-reveal-falls-flat-amid-lack-of-clarity-shifting-focus-back-on-elon-m">robotaxi&#8217;s success in regulatory approval</a>. 
In October, ARK Investment Management said that Tesla&#8217;s driverless ride-hailing plans could unlock $11 trillion in revenue potential, exceeding the total addressable market <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob">that ride-hailing companies</a> Uber Technologies Inc. and LYFT Inc. are targeting.
The Future Fund&nbsp;Managing Partner&nbsp;Gary Black has repeatedly voiced skepticism about&nbsp;Tesla maintaining a monopoly in the unsupervised autonomy market, citing competition from Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)-backed Waymo, Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) and Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) who has already received approval to <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40333845/gary-black-highlights-skepticism-over-teslas-autonomy-ambitions-amid-competition-fr">deploy their autonomous vehicles</a>.
Price Action: Tesla is trading 5.69% higher at $339 on Robinhood&#8217;s overnight trading service. The stock closed at $320.72 in a regular trading session on Friday, gaining 3.07% for the day. In after-hours trading, the stock edged up 0.0062%. Year to date, Tesla's stock has risen by 29.10%, according to&nbsp;<a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/social-media/24/11/42022443/ibm-disney-and-other-large-advertisers-return-to-elon-musks-x-after-a-year-long-boycott-we-super-appreciate" target="_blank" rel="noreferrer noopener">IBM, Disney And Other Large Advertisers Return To Elon Musk's X After A Year-Long Boycott: ‘We Super Appreciate'</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

GOOG

GOOGL

MBLY

TSLA

Tesla Soars Over 5% In Overnight Trading As Trump Administration Reportedly Seeks To Ease FSD Norms

TFI International (TSE:TFII) has released an update. TFI International has announced the retirement of Neil Manning, an independent director, after...

TFI International Announces Director Retirement

Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on A. O. Smith Corporation (AOS – Research Report), TFI Intern...

Analysts Offer Insights on Industrial Goods Companies: A. O. Smith Corporation (AOS), TFI International (TFII) and Herc Holdings (HRI)

Stifel downgraded TFI International (TFII) to Hold from Buy with a price target of $142, down from $158. The company's operating environment and ne...

TFI International downgraded to Hold from Buy at Stifel

Veritas upgraded TFI International (TFII) to Buy from Reduce with a price target of $147, down from $155. Published first on TheFly – the ultimate ...

TFI International upgraded to Buy from Reduce at Veritas

Analysts have been eager to weigh in on the Industrial Goods sector with new ratings on GE Aerospace (GE – Research Report), TFI International (TFI...

Analysts Offer Insights on Industrial Goods Companies: GE Aerospace (GE), TFI International (TFII) and Robert Half (RHI)

National Bank lowered the firm's price target on TFI International (TFII) to C$198 from C$209 and keeps a Sector Perform rating on the shares follo...

TFI International price target lowered to C$198 from C$209 at National Bank

In a report released today, Fadi Chamoun from BMO Capital maintained a Hold rating on TFI International (TFII – Research Report), with a price targ...

TFI International (TFII) Gets a Hold from BMO Capital

TFI International (TSE:TFII) has released an update. TFI International has announced the renewal of its normal course issuer bid, allowing the comp...

TFI International Renews Share Buyback Plan

TFI International (TFII) announced that the Toronto Stock Exchange has approved the renewal of TFI International's normal course issuer bid, or NCI...

TFI International renews normal course issuer bid

Citi raised the firm's price target on TFI International (TFII) to $170 from $158 and keeps a Buy rating on the shares. The firm says sentiment app...

Comments

TFI International

Interés en corto

TFI International (NYSE:TFII) Bolsa, Informe de interés en corto

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL